Peron N, Le Guen P, Andrieu V, Bardot S, Ravilly S, Oudyi M, Dubus J-C
Service de pneumologie, hôpital Bichat, Paris, France.
Rev Mal Respir. 2013 Dec;30(10):832-42. doi: 10.1016/j.rmr.2013.09.005. Epub 2013 Oct 10.
The working group on aerosol therapy (GAT) of the Société de pneumologie de langue française (SPLF) organized its third "Aerosolstorming" in 2012. During the course of one day, different aspects of inhaled therapy were discussed, and these will be treated separately in two articles, this one being the first. Inhaled products represent a large volume of prescriptions both in the community and in hospital settings and they involve various specialties particularly ENT and respiratory care. Technical aspects of the development of these products, their mode of administration and compliance with their indications are key elements for the effective therapeutic use of inhaled treatments. In this first article, we will review issues concerning generic inhaled products, the existence of inhaled antidotes, new anti-infective agents and indications for inhaled pentamidine.
法国语言肺科协会(SPLF)的气雾剂治疗工作组(GAT)于2012年组织了第三次“气雾剂风暴”。在一天的活动中,对吸入治疗的不同方面进行了讨论,这些将在两篇文章中分别论述,本文是第一篇。吸入产品在社区和医院环境中都占了很大一部分处方量,并且涉及多个专科,尤其是耳鼻喉科和呼吸护理。这些产品开发的技术方面、给药方式以及对其适应症的遵循情况是吸入治疗有效应用的关键要素。在这第一篇文章中,我们将综述有关通用吸入产品、吸入解毒剂的存在情况、新型抗感染药物以及吸入喷他脒适应症的问题。